Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's Disease
Status:
Withdrawn
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to learn whether people who are experiencing an MCD (multicentric
Castleman's Disease) flare will improve after taking valganciclovir. MCD is a type of
inflammatory disease associated with Human Herpesvirus 8 (HHV-8). Valganciclovir is FDA
approved for treating a different type of Human Herpesvirus, but not approved for the
treatment of HHV-8. It is therefore considered experimental in this study.